Direct control of CAR T cells through small molecule-regulated antibodies

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Antibody-based therapeutics, including chimeric antigen receptor (CAR) T cells, are rapidly advancing.
• Enhanced potency in next-generation therapies can increase the risk of adverse events.
• Inducible affinity antibody scaffolds offer a potential strategy to mitigate these risks.

Purpose of the Study:

• To develop conditionally activated, single-module CARs with tunable antigen recognition.
• To demonstrate reversible control over CAR T cell activity using an FDA-approved small molecule drug.
• To improve the safety profile of CAR T cell therapy.

Main Methods:

• Engineered single-module CARs where tumor antigen recognition is modulated by a small molecule.
• Assessed CAR T cell cytotoxicity against tumor cells in vitro.
• Evaluated the reversible attenuation of cytotoxicity upon addition of the small molecule drug.

Main Results:

• Conditionally activated CAR T cells exhibited specific tumor cell cytotoxicity comparable to traditional CARs.
• Cytotoxicity was reversibly attenuated by the addition of the small molecule drug.
• Demonstrated exogenous control over CAR T cell activity.

Conclusions:

• Conditionally activated CAR T cells offer a viable strategy for tunable therapeutic activity.
• This approach allows for modulation of CAR T cell activity to enhance safety.
• Exogenous control of CAR T cell activity holds promise for broader therapeutic applications across diseases.